Study Design Selection in Early Clinical Anti-Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests

5Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In antidiabetic drug development, phase I studies usually involve short-term glucose provocations. Multiple designs are available for these provocations (e.g., meal tolerance tests (MTTs) and graded glucose infusions (GGIs)). With a highly nonlinear, complex system as the glucose homeostasis, the various provocations will contribute with different information offering a rich choice. Here, we investigate the most appropriate study design in phase I for several hypothetical mechanisms of action of a study drug. Five drug effects in diabetes therapeutic areas were investigated using six study designs. Power to detect drug effect was assessed using the likelihood ratio test, whereas precision and accuracy of the quantification of drug effect was assessed using stochastic simulation and estimations. An overall summary was developed to aid designing the studies of antihyperglycemic drug development using model-based analysis. This guidance is to be used when the integrated glucose insulin model is used, involving the investigated drug mechanisms of action.

References Powered by Scopus

Glucose clamp technique: A method for quantifying insulin secretion and resistance

7149Citations
N/AReaders
Get full text

Can the pharmaceutical industry reduce attrition rates?

3528Citations
N/AReaders
Get full text

The mechanisms of action of PPARs

2281Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Oral azelaic acid ester decreases markers of insulin resistance in overweight human male subjects

9Citations
N/AReaders
Get full text

A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes

6Citations
N/AReaders
Get full text

Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety

3Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ibrahim, M. M. A., Ghadzi, S. M. S., Kjellsson, M. C., & Karlsson, M. O. (2018). Study Design Selection in Early Clinical Anti-Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests. CPT: Pharmacometrics and Systems Pharmacology, 7(7), 432–441. https://doi.org/10.1002/psp4.12302

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

50%

Researcher 2

25%

Professor / Associate Prof. 1

13%

Lecturer / Post doc 1

13%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 3

33%

Medicine and Dentistry 3

33%

Mathematics 2

22%

Nursing and Health Professions 1

11%

Save time finding and organizing research with Mendeley

Sign up for free